Suppr超能文献

再灌注治疗后急性心肌梗死复发缺血的影响:溶栓治疗与直接血管成形术的比较

Implications of recurrent ischemia after reperfusion therapy in acute myocardial infarction: a comparison of thrombolytic therapy and primary angioplasty.

作者信息

Stone G W, Grines C L, Browne K F, Marco J, Rothbaum D, O'Keefe J, Hartzler G O, Overlie P, Donohue B, Chelliah N

机构信息

Cardiovascular Institute, El Camino Hospital, Mountain View, California, USA.

出版信息

J Am Coll Cardiol. 1995 Jul;26(1):66-72. doi: 10.1016/0735-1097(95)00138-p.

Abstract

OBJECTIVES

The purpose of this study was to examine the incidence and implications of recurrent ischemia after different reperfusion strategies in acute myocardial infarction.

BACKGROUND

The rates and effects of recurrent ischemia after reperfusion with thrombolytic therapy and with primary percutaneous transluminal coronary angioplasty have not been compared.

METHODS

At 12 centers 395 patients presenting within 12 h of the onset of acute myocardial infarction were prospectively randomized to receive recombinant tissue-type plasminogen activator (rt-PA) or primary coronary angioplasty. Sixteen clinical variables were examined by using univariate and multiple logistic regression analysis to identify the predictors of recurrent ischemia. The relation of recurrent ischemic events to patient outcome was analyzed.

RESULTS

Recurrent ischemia developed in 76 patients (19.2%) before hospital discharge, resulting in reinfarction in 18 patients (4.6%) and death in 5 (2.6%). Recurrent ischemia occurred in 56 patients (28.0%) after rt-PA but in only 20 patients (10.3%) after coronary angioplasty (p < 0.0001), directly contributing to a higher rate of death or reinfarction (7.5% vs. 3.1%, p = 0.05), catheterization and revascularization procedures and prolonged hospital stay after thrombolysis. By multivariate analysis, treatment with coronary angioplasty rather than rt-PA was the strongest predictor of freedom from recurrent ischemia. Although the incidence of recurrent ischemia after angioplasty and after rt-PA was similar within the 1st 2 days of admission (9.2% vs. 14.5%, p = 0.11), after hospital day 2 recurrent ischemia occurred in only 2 patients who received primary angioplasty compared with 27 patients who received rt-PA (1.1% vs. 13.5%, p < 0.0001).

CONCLUSIONS

The development of recurrent ischemia adversely affects patient outcome, increasing morbidity, mortality and resource utilization. The much lower rate of recurrent ischemia after primary coronary angioplasty than after rt-PA results in improved survival without reinfarction and allows a shorter, less complicated hospital stay. Given the extremely low rate of recurrent ischemia after hospital day 2, safe early discharge on day 3 after primary coronary angioplasty should be feasible in selected patients with acute myocardial infarction.

摘要

目的

本研究旨在探讨急性心肌梗死不同再灌注策略后再发缺血的发生率及其影响。

背景

溶栓治疗和直接经皮冠状动脉腔内血管成形术(PTCA)再灌注后再发缺血的发生率和影响尚未进行比较。

方法

在12个中心,对395例急性心肌梗死发病12小时内就诊的患者进行前瞻性随机分组,分别接受重组组织型纤溶酶原激活剂(rt-PA)或直接冠状动脉血管成形术治疗。采用单因素和多因素逻辑回归分析16项临床变量,以确定再发缺血的预测因素。分析再发缺血事件与患者预后的关系。

结果

76例患者(19.2%)在出院前发生再发缺血,其中18例(4.6%)再梗死,5例(2.6%)死亡。rt-PA治疗后56例患者(28.0%)发生再发缺血,而冠状动脉血管成形术后仅20例患者(10.3%)发生再发缺血(p<0.0001),这直接导致了更高的死亡或再梗死发生率(7.5%对3.1%,p=0.05),以及溶栓后更高的导管插入术和血管重建术发生率及更长的住院时间。多因素分析显示,冠状动脉血管成形术而非rt-PA治疗是无再发缺血的最强预测因素。尽管入院后头2天血管成形术和rt-PA治疗后再发缺血的发生率相似(9.2%对14.5%,p=0.11),但入院第2天后,接受直接血管成形术的患者中仅2例发生再发缺血,而接受rt-PA治疗的患者中有27例发生再发缺血(1.1%对13.5%,p<0.0001)。

结论

再发缺血的发生对患者预后产生不利影响,增加了发病率、死亡率和资源利用。直接冠状动脉血管成形术后再发缺血的发生率远低于rt-PA治疗后,可提高无再梗死生存率,并缩短住院时间,减少并发症。鉴于入院第2天后再发缺血的发生率极低,对于部分急性心肌梗死患者,直接冠状动脉血管成形术后第3天安全早期出院应是可行的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验